Laura E.Koman

Associate

华盛顿 + 1.202.879.3601

Laura Koman advises health care and life sciences companies on transactional and regulatory matters, with a particular emphasis on digital health.

Laura has advised hospitals, health systems, provider groups, and established and emerging companies concerning e-health topics such as direct-to-consumer telemedicine, provider-to-provider consults, e-prescribing, licensure, remote supervision, reimbursement, patient consent, and corporate structure and corporate practice of medicine issues. She also has participated in structuring various health care transactions, including health care acquisitions, joint ventures, management service agreements, and other arrangements for the provision of professional, practice management, or administrative services. Laura's experience includes counseling clients on health care fraud and abuse issues, including compliance with the Stark Law and Anti-Kickback Statute.

On the life sciences side, Laura advises clients on issues surrounding the regulation of drug, medical device, food, dietary supplement, and cosmetic products by the FDA (Food & Drug Administration), CPSC (Consumer Product Safety Commission), and other federal and state agencies and provides support to clients engaged in life sciences M&A and other transactions, including due diligence.

Laura maintains an active pro bono practice that includes providing advice to nonprofit organizations relating to governance and formation and volunteering with the D.C. Bar Association's Landlord Tenant Resource Center. She also recently represented an individual seeking social security disability benefits as a volunteer for the Washington Legal Clinical for the Homeless.

Laura is a member of the American Health Lawyers Association.

经验

  • KKR acquires IVI-RMA GlobalJones Day acted as U.S. counsel in the €3 billion acquisition of IVI-RMA, a group specialized in assisted reproduction techniques.
  • Riverside portfolio company acquires Jupiter Life Science Consulting (Jupiter)Jones Day advised The Riverside Company in connection with the acquisition and financing by portfolio company Red Nucleus of Jupiter Life Science Consulting (Jupiter), a leading provider of commercial and market access strategies for global pharma, biotech, and medical device companies with its primary focus in rare disease, hematology/oncology, metabolic, and neurology therapeutic areas.
  • Riverside portfolio company acquires RockpointeJones Day represented The Riverside Company in connection with the acquisition by portfolio company Clinical Education Alliance (CEA) of Rockpointe, Inc., a premier healthcare education company providing accredited continuing education activities and related training for healthcare professionals.
  • Nurx merges with Thirty MadisonJones Day provided healthcare and data privacy counsel to Nurx in connection with its merger with Thirty Madison, a leading digital healthcare company operating across the U.S.
  • Riverside portfolio company acquires Medical Marketing Solutions GroupJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Medical Marketing Solutions Group (MMSG), a leading medical education company that provides strategic services, scientific and medical communications, and operational and event management services to global biopharmaceutical companies.
  • City of Hope acquires Cancer Treatment Centers of AmericaJones Day advised City of Hope, a world-renowned, National Cancer Institute (NCI)-designated comprehensive cancer research and treatment organization, in connection with its acquisition of Cancer Treatment Centers of America, a network of oncology hospitals and outpatient care centers across the United States.
  • Misonix merges with BioventusJones Day represented Misonix, Inc. (Nasdaq: MSON) in its acquisition by Bioventus Inc. (Nasdaq: BVS).
  • PWNHealth and Home Access Health Corporation sold to Everlywell, forming Everly HealthJones Day advised PWNHealth LLC and Home Access Health Corporation in its sale to Everlywell, a leading digital health company, and forming Everly Health.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Riverside portfolio company acquires iTakeControlJones Day represented The Riverside Company in connection with the acquisition by portfolio company Red Nucleus, a premier provider of learning, performance, and process solutions for the life sciences industry, of iTakeControl, a leading provider of clinical operations and medical affairs technology and services focused on rare disease and specialty pharma.
  • Smith & Nephew acquires Extremity Orthopedics business of Integra LifeSciences Holdings Corporation for $240 millionJones Day advised Smith & Nephew plc, the global medical technology company, in its acquisition of the Extremity Orthopedics business of Integra LifeSciences Holdings Corporation (NASDAQ: IART) for $240 million on a cash and debt-free basis.
  • SOC Telemed merges with Healthcare Merger Corp.Jones Day provided healthcare and general corporate counsel to SOC Telemed, Inc. in its $720 million merger with Healthcare Merger Corp.
  • Olive Tree Ventures participates in $33 million investment in Lemonaid HealthJones Day represented Olive Tree Ventures as health regulatory and privacy counsel in connection with its investment in Lemonaid Health, a convenient, affordable, on-demand platform for accessing healthcare online.
  • UPMC subsidiary Curavi Health combined with CarePointe and U.S. Health Systems to form Arkos HealthJones Day advised University of Pittsburgh Medical Center (UPMC) in the business combination of its subsidiary Curavi Health, Inc. with CarePointe and U.S. Health Systems to form Arkos Health, a company that will provide virtual care solutions and health insights to vulnerable populations across the United States.
  • Riverside sells ActivStyleJones Day advised The Riverside Company in its sale of ActivStyle, a distributor of consumable medical supplies with an emphasis on incontinence products.
  • Digital health company expands telehealth programming in response to the COVID-19 public health crisisJones Day represented a digital health company in the expansion of their telehealth programming in response to the COVID-19 public health crisis.
  • National diagnostic clinician network expands telehealth programming in response to COVID-19 public health crisisJones Day represented a national diagnostic clinician network in their expansion of telehealth programming in response to the COVID-19 public health crisis.
  • Telehealth company expands programming in response to COVID-19 public health crisisJones Day represented a telehealth company in the expansion of their telehealth programming in response to the COVID-19 public health crisis and related health regulatory and contracting matters.
  • Telemedicine provider expands telehealth programming in response to COVID-19 public health crisisJones Day represented a telemedicine provider in their expansion of telehealth programming in response to the COVID-19 public health crisis.
  • Large critical infrastructure employer considers implementing COVID-19 testing program for employeesJones Day represented a large critical infrastructure employer during the COVID-19 crisis to consider and assess appropriate protocols and policies for implementing an employee COVID-19 testing program at its sites. This included counseling on myriad federal, state, and local legal and regulatory frameworks as well as forming appropriate partnerships.
  • 演讲

    • August 1, 2019
      11th Annual mHealth and Telehealth World Summit―Addressing the Legal and Regulatory Barriers to Expand Telehealth Capabilities
    • April 14, 2019
      ATA19—Direct-to-Consumer Telemedicine – Lessons Learned and Strategies for Advancing Policy
    • March 22, 2019
      Institute on Medicare and Medicaid Payment Issues—2019 Changes to Medicare Reimbursement for Telehealth and Communication Technology Based Services
    • October 10, 2018
      AHLA Telemedicine Webinar Series—Part I: Fundamentals of Telemedicine Legal and Regulatory